Boston Scientific’s RESPI Study Signals Quiet Push Into Smart Respiratory Monitoring
Boston Scientific (BSX) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Boston Scientific (BSX) has launched the Respiration Measured Via End-tidal CO2 and Spirometry Study, or RESPI, to track how well a new mask measures breathing rate versus standard tools. The goal is to confirm that simple mask-based sensors can give reliable respiratory data, which may support future smart monitoring products and expand the firm’s digital health reach.
The study tests a wearable respiration mask device used at rest and, in some cases, during light exercise. The mask tracks breathing in real time and its readings are compared with established methods, aiming to show that a small, comfortable device can replace bulkier clinical equipment for routine monitoring.
RESPI is an observational study that follows groups of healthy adults rather than assigning treatments at random. Researchers will watch how breathing data from the mask matches readings from existing measures over time, with the main goal of proving reliable detection in normal and exercise conditions.
The trial is listed as not yet recruiting, with initial submission dated March 16, 2026, showing the work is still at the setup stage. The last update on April 16, 2026, signals recent activity on protocol details, while primary and final completion dates have not been posted yet, highlighting very early development.
For investors, this update points to Boston Scientific’s push into wearable and sensor-driven monitoring, a fast-growing segment that could complement its core cardiac and interventional lines. While near-term revenue impact is limited, validation of this mask platform could support longer-term growth and help BSX compete with Medtronic, Abbott, and consumer-focused players moving into clinical-grade respiratory tracking.
The RESPI study remains in its startup phase and is currently updated on the ClinicalTrials portal, where investors can track future milestones and detailed protocol changes as they appear.
To learn more about BSX’s potential, visit the Boston Scientific drug pipeline page.
